Search Medical Condition
Please enter condition
Please choose location
 

Cuneo, Italy Clinical Trials

A listing of Cuneo, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (18) clinical trials

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

In this study everolimus will be administered in combination with exemestane, which is an irreversible steroidal aromatase inactivator that has demonstrated efficacy in the treatment of postmenopausal patients with ABC. Exemestane is indicated for adjuvant treatment of postmenopausal women with HR+ EBC who have received two to three years of ...

Phase

0.0 miles

Learn More »

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

Since the HZ/su vaccine has not yet been licensed and marketed, this study is being conducted to enable potentially eligible subjects who previously received placebo in ZOSTER-006 (NCT01165177) or ZOSTER-022 (NCT01165229) to receive the HZ/su vaccine. Study ZOSTER-056 is an open-label, multi-centric and single arm study to cross-vaccinate and collect ...

Phase

0.0 miles

Learn More »

Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.

The incidence of delayed thrombocytopenia in patients who undergo allogeneic hemopoietic stem cell transplant (SCT) is nearly 20-40% (1-2). Chronic graft versus host disease (cGVHD) seems to be the most frequent pathologic condition associated with post SCT delayed thrombocytopenia. Previous studies indicated the occurrence of delayed thrombocytopenia as a poor ...

Phase

0.0 miles

Learn More »

Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset Crisis

Stroke is the most common cause of seizures in the elderly and seizures are among the most common sequelae of stroke. About 10% of patients experience seizures since stroke onset up to several years (Silverman 2002). Arbitrarly a cut point of 2 weeks divide early seizures from late seizures (Honey ...

Phase

0.0 miles

Learn More »

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I Stage II or Stage III HER2-Positive Breast Cancer

OBJECTIVES: Primary - To evaluate if 3 months of trastuzumab (Herceptin®) administered according to the Finnish protocol (9-weekly administrations) is not inferior to 12 months (18 three-weekly administrations) in a standard chemotherapy protocol, in terms of disease-free survival, in patients with HER2-positive early breast cancer. - To determine overall survival ...

Phase

0.0 miles

Learn More »